Irritable Bowel Syndrome Characterized by Constipation Clinical Trial
Official title:
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
To evaluate the efficacy on abdominal symptoms (abdominal bloating, abdominal discomfort, and abdominal pain) and safety of linaclotide 290 μg administered orally to patients with IBS-C.
This study consists of a 12-week Treatment Period followed by 4-week Randomized Withdrawal (RW) Period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01622972 -
Mode of Action of Moviprep
|
Phase 4 | |
| Recruiting |
NCT03687814 -
Low FODMAP Plus PEG 3350 for the Treatment of Patients With Irritable Bowel Syndrome-Constipation
|
N/A | |
| Completed |
NCT01722318 -
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
|
Phase 2 | |
| Recruiting |
NCT04214470 -
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS
|
||
| Completed |
NCT02493452 -
Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
|
Phase 3 | |
| Completed |
NCT00948818 -
Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
|
Phase 3 | |
| Recruiting |
NCT03226145 -
Reclassifying Constipation Using Imaging and Manometry
|
N/A | |
| Completed |
NCT02732743 -
Food Supplement Physiomanna® Baby in Pediatric Patients
|
N/A | |
| Terminated |
NCT02837783 -
A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
|
Phase 4 | |
| Not yet recruiting |
NCT03923322 -
Botanical Tincture for Symptoms of Irritable Bowel Syndrome
|
Phase 2 | |
| Completed |
NCT02387359 -
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
|
Phase 3 |